

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger

Judit U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Albert L. Ferro* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Bunon Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes

Flosepps: (serroria, frank R. Cottingham Christine M. Uhulier Rae Lynn P. Guest George S. Bardmesser Daniel A. Klein* Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller* LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford* Helene C. Carlson Timothy A. Doyle* Gaby L. Longsworth Lori A. Gordon* Nicole D. Dretar*

Corres. and Mail

Ayou C. Iyer"
Laura A. Vogel

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Michelle K. Holoubek
Robert H. DeSelms
Simon J. Elliott

AF Frw

Julie A. Heider Mita Mukherjee Scott M. Woodhouse Michael G. Penn Christopher J. Walsh

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

December 7, 2004

WRITER'S DIRECT NUMBER: (202) 772-8615 INTERNET ADDRESS: FRANKC@SKGF.COM

Mail Stop AF

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 09/964,667; Filed: September 28, 2001

For: Transgenic Animals and Cell Lines for Screening Drugs Effective for

the Treatment or Prevention of Alzheimer's Disease

Inventors:

de la Monte et al.

Our Ref:

0609.4370005/RWE/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Amendment and Reply Under 37 C.F.R. § 1.116 along with Exhibit A; and
- 2. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

?

Commissioner for Patents December 7, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Franke R. Cattilin

Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

FRC/pcd Encls.

340130v1



Amendment Under 37 C.F.R. § 1.116 Expedited Procedure – Art Unit 1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

de la Monte et al.

Appl. No.: 09/964,667

Filed: September 28, 2001

For: Transgenic Animals and Cell Lines for Screening Drugs Effective for

the Treatment or Prevention of

Alzheimer's Disease

Confirmation No.: 3648

Art Unit: 1635

Examiner: McGarry, Sean

Atty. Docket: 0609.4370005/RWE/FRC

Amendment and Reply Under 37 C.F.R. § 1.116

Mail Stop AF

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated September 9, 2004, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.